Signature quality attributes of CD146+ mesenchymal stem/stromal cells correlate with high therapeutic and secretory potency
©AlphaMed Press 2020..
CD146+ bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) play key roles in the perivascular niche, skeletogenesis, and hematopoietic support; however, comprehensive evaluation of therapeutic potency has yet to be determined. In this study, in vitro inflammatory priming to crude human BM-MSCs (n = 8) captured a baseline of signature responses, including enriched CD146+ with coexpression of CD107aHigh , CXCR4High , and LepRHigh , transcriptional profile, enhanced secretory capacity, and robust immunomodulatory secretome and function, including immunopotency assays (IPAs) with stimulated immune cells. These signatures were significantly more pronounced in CD146+ (POS)-sorted subpopulation than in the CD146- (NEG). Mechanistically, POS BM-MSCs showed a markedly higher secretory capacity with significantly greater immunomodulatory and anti-inflammatory protein production upon inflammatory priming compared with the NEG BM-MSCs. Moreover, IPAs with stimulated peripheral blood mononuclear cells and T lymphocytes demonstrated robust immunosuppression mediated by POS BM-MSC while inducing significant frequencies of regulatory T cells. in vivo evidence showed that POS BM-MSC treatment promoted pronounced M1-to-M2 macrophage polarization, ameliorating inflammation/fibrosis of knee synovium and fat pad, unlike treatment with NEG BM-MSCs. These data correlate the expression of CD146 with innately higher immunomodulatory and secretory capacity, and thus therapeutic potency. This high-content, reproducible evidence suggests that the CD146+ (POS) MSC subpopulation are the mediators of the beneficial effects achieved using crude BM-MSCs, leading to translational implications for improving cell therapy and manufacturing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Stem cells (Dayton, Ohio) - 38(2020), 8 vom: 07. Aug., Seite 1034-1049 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bowles, Annie C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD107a |
|---|
| Anmerkungen: |
Date Completed 09.07.2021 Date Revised 09.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/stem.3196 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309631882 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309631882 | ||
| 003 | DE-627 | ||
| 005 | 20231225134336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/stem.3196 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309631882 | ||
| 035 | |a (NLM)32379908 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bowles, Annie C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Signature quality attributes of CD146+ mesenchymal stem/stromal cells correlate with high therapeutic and secretory potency |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.07.2021 | ||
| 500 | |a Date Revised 09.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©AlphaMed Press 2020. | ||
| 520 | |a CD146+ bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) play key roles in the perivascular niche, skeletogenesis, and hematopoietic support; however, comprehensive evaluation of therapeutic potency has yet to be determined. In this study, in vitro inflammatory priming to crude human BM-MSCs (n = 8) captured a baseline of signature responses, including enriched CD146+ with coexpression of CD107aHigh , CXCR4High , and LepRHigh , transcriptional profile, enhanced secretory capacity, and robust immunomodulatory secretome and function, including immunopotency assays (IPAs) with stimulated immune cells. These signatures were significantly more pronounced in CD146+ (POS)-sorted subpopulation than in the CD146- (NEG). Mechanistically, POS BM-MSCs showed a markedly higher secretory capacity with significantly greater immunomodulatory and anti-inflammatory protein production upon inflammatory priming compared with the NEG BM-MSCs. Moreover, IPAs with stimulated peripheral blood mononuclear cells and T lymphocytes demonstrated robust immunosuppression mediated by POS BM-MSC while inducing significant frequencies of regulatory T cells. in vivo evidence showed that POS BM-MSC treatment promoted pronounced M1-to-M2 macrophage polarization, ameliorating inflammation/fibrosis of knee synovium and fat pad, unlike treatment with NEG BM-MSCs. These data correlate the expression of CD146 with innately higher immunomodulatory and secretory capacity, and thus therapeutic potency. This high-content, reproducible evidence suggests that the CD146+ (POS) MSC subpopulation are the mediators of the beneficial effects achieved using crude BM-MSCs, leading to translational implications for improving cell therapy and manufacturing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD107a | |
| 650 | 4 | |a CD146 | |
| 650 | 4 | |a immunomodulation | |
| 650 | 4 | |a infrapatellar fat pad fibrosis | |
| 650 | 4 | |a macrophage polarization | |
| 650 | 4 | |a mesenchymal stem/stromal cells | |
| 650 | 4 | |a synovitis | |
| 650 | 7 | |a CD146 Antigen |2 NLM | |
| 650 | 7 | |a MCAM protein, human |2 NLM | |
| 700 | 1 | |a Kouroupis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Willman, Melissa A |e verfasserin |4 aut | |
| 700 | 1 | |a Perucca Orfei, Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Ashutosh |e verfasserin |4 aut | |
| 700 | 1 | |a Correa, Diego |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cells (Dayton, Ohio) |d 1994 |g 38(2020), 8 vom: 07. Aug., Seite 1034-1049 |w (DE-627)NLM074655477 |x 1549-4918 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:8 |g day:07 |g month:08 |g pages:1034-1049 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/stem.3196 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 8 |b 07 |c 08 |h 1034-1049 | ||